GlassScriptPhysician profile
Tory August Torma
NPI 1194255448
$15,210.65
in general payments reported to CMS, 2019-2025
30 companies · $3,789 in 2025
The $3,789 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.97 · 2020: $114 · 2021: $881 · 2022: $1,069 · 2023: $1,337 · 2024: $8,009 · 2025: $3,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,625 · Food and Beverage: $3,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,625.00 |
| Food and Beverage | $3,510.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,325.37 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $631.84 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $595.57 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $530.47 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $256.67 | 2021-2025 | Repatha, Otezla, Tezspire |
| Biohaven Pharmaceutical Holding Company LTD. | $227.63 | 2022 | |
| Boston Scientific Corporation | $182.51 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $172.19 | 2021-2025 | Farxiga, Breztri |
| Pfizer INC. | $141.57 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $127.24 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $102.83 | 2022-2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $101.49 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.04 | 2023-2024 | Jardiance |
| Almatica Pharma LLC | $93.82 | 2021-2023 | Gralise, Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $85.51 | 2024-2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $80.94 | 2025 | Fanapt |
| Astellas Pharma US INC | $80.21 | 2023-2025 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $61.78 | 2025 | Auvelity |
| Exact Sciences Corporation | $42.30 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $36.46 | 2021 | |
| Corcept Therapeutics | $32.57 | 2024-2025 | Korlym |
| Lundbeck LLC | $31.91 | 2024-2025 | Rexulti, Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $31.80 | 2025 | |
| Phathom Pharmaceuticals, INC. | $23.13 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.05 | 2025 | Caplyta |
| Verona Pharma, INC. | $19.15 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $16.50 | 2020 | |
| Allergan, INC. | $16.42 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.64 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.07 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tory Torma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.